Shandong Xinhua Pharmaceutical Wins China Approval for Prednisolone Acetate API
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for its Prednisolone Acetate API. This approval is expected to enhance the company's hormone product line and competitiveness. Investors are advised to be cautious due to potential industry policy and market changes. The announcement was made via the Hong Kong Stock Exchange's Issuer Information Service.
Shandong Xinhua Pharmaceutical Company Limited has announced that it has received the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients from the National Medical Products Administration for its product, Prednisolone Acetate. This approval is expected to further enrich the company’s hormone product line and enhance its core competitiveness. The announcement notes that the pharmaceutical sales business remains susceptible to changes in industry policies and market environment, advising investors to exercise caution. There is no indication that the grant or approval was obtained by any organizations other than Shandong Xinhua Pharmaceutical Company Limited. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Xinhua Pharmaceutical Company Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251127-11930109), on November 27, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
